These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Use of green fluorescent protein to assess urease gene expression by uropathogenic Proteus mirabilis during experimental ascending urinary tract infection. Zhao H; Thompson RB; Lockatell V; Johnson DE; Mobley HL Infect Immun; 1998 Jan; 66(1):330-5. PubMed ID: 9423875 [TBL] [Abstract][Full Text] [Related]
4. Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract. Scavone P; Rial A; Umpierrez A; Chabalgoity A; Zunino P Microbiol Immunol; 2009 Apr; 53(4):233-40. PubMed ID: 19714860 [TBL] [Abstract][Full Text] [Related]
5. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis. Habibi M; Asadi Karam MR; Bouzari S APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627 [TBL] [Abstract][Full Text] [Related]
6. Native flagellin does not protect mice against an experimental Proteus mirabilis ascending urinary tract infection and neutralizes the protective effect of MrpA fimbrial protein. Scavone P; Umpiérrez A; Rial A; Chabalgoity JA; Zunino P Antonie Van Leeuwenhoek; 2014 Jun; 105(6):1139-48. PubMed ID: 24771125 [TBL] [Abstract][Full Text] [Related]
7. In vivo phase variation of MR/P fimbrial gene expression in Proteus mirabilis infecting the urinary tract. Zhao H; Li X; Johnson DE; Blomfield I; Mobley HL Mol Microbiol; 1997 Mar; 23(5):1009-19. PubMed ID: 9076737 [TBL] [Abstract][Full Text] [Related]
8. New aspects of RpoE in uropathogenic Proteus mirabilis. Liu MC; Kuo KT; Chien HF; Tsai YL; Liaw SJ Infect Immun; 2015 Mar; 83(3):966-77. PubMed ID: 25547796 [TBL] [Abstract][Full Text] [Related]
9. Determination immunogenic property of truncated MrpH.FliC as a vaccine candidate against urinary tract infections caused by Proteus mirabilis. Bameri Z; Asadi Karam MR; Habibi M; Ehsani P; Bouzari S Microb Pathog; 2018 Jan; 114():99-106. PubMed ID: 29138084 [TBL] [Abstract][Full Text] [Related]
10. Identification of protease and rpoN-associated genes of uropathogenic Proteus mirabilis by negative selection in a mouse model of ascending urinary tract infection. Zhao H; Li X; Johnson DE; Mobley HLT Microbiology (Reading); 1999 Jan; 145 ( Pt 1)():185-195. PubMed ID: 10206698 [TBL] [Abstract][Full Text] [Related]
11. UNAM-HIMFG Bacterial Lysate Activates the Immune Response and Inhibits Colonization of Bladder of Balb/c Mice Infected with the Uropathogenic CFT073 Acevedo-Monroy SE; Hernández-Chiñas U; Rocha-Ramírez LM; Medina-Contreras O; López-Díaz O; Ahumada-Cota RE; Martínez-Gómez D; Huerta-Yepez S; Tirado-Rodríguez AB; Molina-López J; Castro-Luna R; Martínez-Cristóbal L; Rojas-Castro FE; Chávez-Berrocal ME; Verdugo-Rodríguez A; Eslava-Campos CA Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337365 [TBL] [Abstract][Full Text] [Related]
12. Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection. Alamuri P; Eaton KA; Himpsl SD; Smith SN; Mobley HL Infect Immun; 2009 Feb; 77(2):632-41. PubMed ID: 19029299 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model. Habibi M; Asadi Karam MR; Bouzari S Int Immunopharmacol; 2015 Sep; 28(1):70-8. PubMed ID: 26033493 [TBL] [Abstract][Full Text] [Related]
14. Construction and evaluation of the immune protection of a recombinant divalent protein composed of the MrpA from MR/P fimbriae and flagellin of Proteus mirabilis strain against urinary tract infection. Habibi M; Asadi Karam MR; Bouzari S Microb Pathog; 2018 Apr; 117():348-355. PubMed ID: 29452195 [TBL] [Abstract][Full Text] [Related]
15. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis. Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections. Pellegrino R; Galvalisi U; Scavone P; Sosa V; Zunino P FEMS Immunol Med Microbiol; 2003 May; 36(1-2):103-10. PubMed ID: 12727373 [TBL] [Abstract][Full Text] [Related]